文献速递物质与行为成瘾

132113名欧洲裔23andMe研究参与者中问题性阿片类药物处方使用的全基因组关联研究

Genome-wide association study of problematic opioid prescription use in 132,113 23andMe research participants of European ancestry.
PubMed 文献 · Mol Psychiatry · 2021-11-02

在132113名欧洲裔23andMe研究参与者(21%为病例)中,对问题性阿片类药物使用(POU)进行全基因组关联研究(GWAS),识别出两个全基因组显著位点(rs3791033,KDM4A内含子变异;rs640561,LRRIQ3附近基因间变异)。POU与阿片类药物使用障碍及阿片类药物依赖的现有最大GWAS呈正遗传相关(rg分别为0.64和0.80),并与酒精依赖、吸烟起始、止痛药物摄入、重度抑郁症、慢性疼痛、失眠和孤独感等存在遗传相关。作者结论认为,阿片类药物误用可在人群队列中测量,为理解OUD遗传基础提供了经济有效的补充策略。

要点

  • POU与阿片类药物使用障碍及阿片类药物依赖的现有最大GWAS呈正遗传相关(rg=0.64和0.80)。
  • 识别出两个全基因组显著位点:rs3791033(KDM4A内含子变异)和rs640561(LRRIQ3附近基因间变异)。
  • POU与酒精依赖(rg=0.74)、吸烟起始(rg=0.63)、止痛药物摄入(rg=0.49)、重度抑郁症(rg=0.44)、慢性疼痛(rg=0.42)、失眠(rg=0.39)、孤独感(rg=0.28)等存在遗传相关。

核心结论

  • 作者结论认为,阿片类药物误用可在人群队列中测量,为理解阿片类药物使用障碍的遗传基础提供了经济有效的补充策略。

研究设计与样本

  • 在132113名欧洲裔23andMe研究参与者(21%为病例)中,对问题性阿片类药物使用(POU)进行全基因组关联研究(GWAS)。

主要发现

  • 识别出两个全基因组显著位点:rs3791033(KDM4A内含子变异)和rs640561(LRRIQ3附近基因间变异)。
  • POU与阿片类药物使用障碍及阿片类药物依赖的现有最大GWAS呈正遗传相关(rg=0.64和0.80)。
  • POU与酒精依赖(rg=0.74)、吸烟起始(rg=0.63)、止痛药物摄入(rg=0.49)、重度抑郁症(rg=0.44)、慢性疼痛(rg=0.42)、失眠(rg=0.39)和孤独感(rg=0.28)存在遗传相关。
  • POU与风险承担呈正遗传相关(rg=0.38),但控制风险承担后,这些遗传相关的幅度或方向未发生实质改变,提示POU并非简单地反映对风险行为的遗传倾向。
  • 全表型和实验室范围关联分析发现,POU还与呼吸衰竭、失眠、缺血性心脏病以及代谢和血液相关生物标志物等表型相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The growing prevalence of opioid use disorder (OUD) constitutes an urgent health crisis. Ample evidence indicates that risk for OUD is heritable. As a surrogate (or proxy) for OUD, we explored the genetic basis of using prescription opioids 'not as prescribed'. We hypothesized that misuse of opiates might be a heritable risk factor for OUD. To test this hypothesis, we performed a genome-wide association study (GWAS) of problematic opioid use (POU) in 23andMe research participants of European ancestry (N = 132,113; 21% cases). We identified two genome-wide significant loci (rs3791033, an intronic variant of KDM4A; rs640561, an intergenic variant near LRRIQ3). POU showed positive genetic correlations with the two largest available GWAS of OUD and opioid dependence (rg = 0.64, 0.80, respectively). We also identified numerous additional genetic correlations with POU, including alcohol dependence (rg = 0.74), smoking initiation (rg = 0.63), pain relief medication intake (rg = 0.49), major depressive disorder (rg = 0.44), chronic pain (rg = 0.42), insomnia (rg = 0.39), and loneliness (rg = 0.28). Although POU was positively genetically correlated with risk-taking (rg = 0.38), conditioning POU on risk-taking did not substantially alter the magnitude or direction of these genetic correlations, suggesting that POU does not simply reflect a genetic tendency towards risky behavior. Lastly, we performed phenome- and lab-wide association analyses, which uncovered additional phenotypes that were associated with POU, including respiratory failure, insomnia, ischemic heart disease, and metabolic and blood-related biomarkers. We conclude that opioid misuse can be measured in population-based cohorts and provides a cost-effective complementary strategy for understanding the genetic basis of OUD.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Sanchez-Roige S, Fontanillas P, Jennings MV, et al. Genome-wide association study of problematic opioid prescription use in 132,113 23andMe research participants of European ancestry. Mol Psychiatry. 2021. PMID: 34728798. doi:10.1038/s41380-021-01335-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。